Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Efficacy and Safety of Interferon Beta-1a (Avonex) Appears Unaffected by Gender of Patient: Presented at ECTRIMS By Bruce Sylvester THESSALONIKI, GREECE -- October 3, 2005 -- Treatment of multiple sclerosis with interferon beta-1a (Avonex) is equally efficacious in men and women, with similar safety profiles in both genders, researchers reported here on September 29th at the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). "Some other studies had suggested that the treatment effect might be different, but we didn't find this result in this meta-analysis of the trials that we have done with the drug," said investigator and presenter Alfred Sandrock, MD, PhD, vice-president of medical research, Biogen Idec, Inc., Cambridge, Massachusetts, United States. "Moreover, the side-effect profile was also similar between men and women." The investigators pooled data from 5 clinical studies of MS and compared the treatment response of male and female subjects to interferon beta-1a. They used 4 efficacy endpoints -- time to first relapse, annualised relapse rate, time to 1-point sustained Expanded Disability Status Scale progression, and gadolinium-enhancing lesions. They also pooled and analysed safety data. The researchers included 1406 subjects in the analyses; 1027 female subjects and 379 male subjects. For women, median time to first relapse was 495 days. For men it was 505 days. The annualised relapse rate was 0.68 for women and 0.65 for men. The overall rate of flu-like symptoms was 69% for women and 74% for men. The investigators reported clinically notable increases in alanine aminotransferase related tests in 5% of women and 6% of men, and 3% of both females and males showed increases in aspartate aminotransferase tests. Analyses using the 4 efficacy endpoints showed that the effect of interferon beta-1a was favorable and similarly so for women and men. The analyses also showed a similar safety profile for both genders. "It appears that the benefit-risk ratio is very similar whether you are a man or a woman who takes this drug," Dr. Sandrock added. The research was supported by Biogen Idec, Inc. [Presentation title: A Study of the Effect of Gender on Interferon Beta-1a (Avonex(R) 30 Mcg) Treatment in Patients With Multiple Sclerosis. Poster 309] E-mail this page to a friend or colleague! To print, use this version